TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)
14 oct. 2020 04h41 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 14, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19
15 juil. 2020 07h23 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan , July 15, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...